Tracking the genetic changes of arboviruses in New Caledonia and the effects of Wolbachia
Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
This study is trying to see how arboviruses like dengue and Zika have changed over time in New Caledonia and how the Wolbachia bacterium introduced in 2019 affects them by looking at blood samples from patients with symptoms.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 2 Years and up |
| Sex | All |
| Sponsor | Institut Pasteur Industry-sponsored |
| Locations | 1 site (Dumbéa Sur Mer, Nouvelle-Calédonie) |
| Trial ID | NCT04615364 on ClinicalTrials.gov |
What this trial studies
This observational study aims to monitor the genetic evolution of arboviruses such as dengue, Zika, and chikungunya in New Caledonia from 1995 to 2024, particularly focusing on the impact of the Wolbachia bacterium introduced in 2019. Researchers will collect blood samples from patients showing symptoms of arbovirus infections and confirm diagnoses through RT-qPCR. The study will utilize molecular characterization techniques, including RNA isolation and sequencing, to construct phylogenetic trees that illustrate the evolution of these viruses. The findings will enhance understanding of arbovirus transmission and the role of Wolbachia in altering viral diversity.
Who should consider this trial
Good fit: Ideal candidates include individuals who have exhibited clinical signs of arbovirus infection within the last week and have confirmed diagnoses.
Not a fit: Patients who do not have a confirmed arbovirus infection or whose samples were collected more than 7 days after symptom onset may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved strategies for controlling arbovirus outbreaks and enhancing public health responses.
How similar studies have performed: Other studies have shown promise in using Wolbachia to control arbovirus transmission, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Appearance of clinical signs suggestive of an infection with an arbovirus in the 7 days preceding the blood sample, * Diagnostic confirmation by RT-qPCR of mono-infection with dengue virus or another arbovirus. * Patients or their representative (s) informed of the possible secondary use for research purposes of the samples initially taken for diagnostic purposes and their derivatives, and who have not since expressed their opposition to the secondary use of the samples diagnostics or their derivatives for research, Exclusion Criteria: * Documented opposition from a patient or his representative (s) * Previously established viral load too low. * Sample obtained from a sample taken more than 7 days after the appearance of clinical signs of infection.
Where this trial is running
Dumbéa Sur Mer, Nouvelle-Calédonie
- Centre Hospitalier Territorial — Dumbéa Sur Mer, Nouvelle-Calédonie, France (Recruiting)
Study contacts
- Principal investigator: Myrielle Dupont-Rouzeyrol, PhD — Institut Pasteur de Nouvelle-Calédonie
- Study coordinator: Myrielle Dupont-Rouzeyrol, PhD
- Email: mdupont@pasteur.nc
- Phone: +687 27 75 30
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.